Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome. by Amer, Wafa et al.
1SCIentIfIC REPORTS | 7: 11069  | DOI:10.1038/s41598-017-11345-3
www.nature.com/scientificreports
Evolution analysis of 
heterogeneous non-small cell 
lung carcinoma by ultra-deep 
sequencing of the mitochondrial 
genome
Wafa Amer1, Csaba Toth1, Erik Vassella2, Jeannine Meinrath1, Ulrike Koitzsch1, Anne Arens3, 
Jia Huang1, Hannah Eischeid1, Alexander Adam1, Reinhard Buettner1,4,5,6, Andreas Scheel1,4,5, 
Stephan C. Schaefer1,4,5 & Margarete Odenthal1,4,6
Accurate assessment of tumour heterogeneity is an important issue that influences prognosis and 
therapeutic decision in molecular pathology. Due to the shortage of protective histones and a limited 
DNA repair capacity, the mitochondrial (mt)-genome undergoes high variability during tumour 
development. Therefore, screening of mt-genome represents a useful molecular tool for assessing 
precise cell lineages and tracking tumour history. Here, we describe a highly specific and robust 
multiplex PCR-based ultra-deep sequencing technology for analysis of the whole mt-genome (wmt-seq) 
on low quality-DNA from formalin-fixed paraffin-embedded tissues. As a proof of concept, we applied 
the wmt-seq technology to characterize the clonal relationship of non-small cell lung cancer (NSCLC) 
specimens with multiple lesions (N = 43) that show either different histological subtypes (group I) or 
pulmonary adenosquamous carcinoma as striking examples of a mixed-histology tumour (group II). The 
application of wmt-seq demonstrated that most samples bear common mt-mutations in each lesion 
of an individual patient, indicating a single cell progeny and clonal relationship. Hereby we show the 
monoclonal origin of histologically heterogeneous NSCLC and demonstrate the evolutionary relation of 
NSCLC cases carrying heteroplasmic mt-variants.
Tumour tracking and evolution analysis to identify the intra-tumour clonal structure or history of multiple 
tumour lesions within the same patient are currently evolving into important diagnostic tools for the precision 
treatment of malignant neoplasias1–3.
The human mitochondrial genome is a circular DNA molecule that encompasses ~16.5 kbp and contains 
37 genes [http://www.mitomap.org]. Each mitochondrion contains 10–15 copies of mitochondrial (mt) DNA, 
which is predisposed to a 10-fold higher accumulation of mutations than nuclear DNA4. This is due to the fact 
that the mitochondria are exposed to high levels of reactive oxygen species (ROS)5, 6. Furthermore, mitochon-
dria lack protective histones and an efficient DNA repair system, which results in limited defence mechanisms 
against endogenous or exogenous damaging agents such as oxidative stress and leads to a high mutation rate7, 8. 
During tumour development, some mutated mtDNA copies may confer selective advantage or disadvantage on 
tumour cells during mt-DNA replication, cell growth and infiltration, resulting in clonal expansion or loss of 
the mutated mtDNA copies. Therefore, mutations do not affect only a proportion of the mitochondrial genome 
copies (heteroplasmic mutations), but often affect all copies of a tumour lesion (homoplasmic mutations)9, 10. The 
resulting high mutation rate and mt-variability, the high number of mt-DNA copies within each cell, and the fact 
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that most of the somatic mtDNA mutations are homoplasmic9, 10, make the mt-genome an ideal target for tumour 
cell tracking11, 12.
In the present study, we established an ultra-deep sequencing approach, identifying mt-variants of the entire 
mt-genome on formalin-fixed paraffin-embedded (FFPE) tumour lesions. This novel technology of ‘whole mito-
chondrial DNA ultra-deep sequencing’ (wmt-seq) was applied to non-small cell lung cancer (NSCLC), which 
represents 80% of all lung cancer. The two main histological subtypes of NSCLC are adenocarcinoma (AD), 
which accounts for 50% NSCLC, and squamous cell carcinoma (SQ), which accounts for 40%13. However, NSCLC 
exhibits a variety of morphological and molecular features14. Moreover, tumour-heterogeneity is a common and 
well-recognised phenomenon in NSCLC, much more than in other solid tumours15. The accurate clonal assess-
ment of NSCLC to either distinguish clinically challenging synchronous and metachronous tumours or differ-
entiate between multiple primary tumour lesions from metastases is an essential basis for prognostic estimation 
and therapeutic decision16.
In order to study the clonal relationship, we used two NSCLC cohorts characterized by i) multiple lesions with 
different histology within the same patients or ii) tumours with heterogeneous, adenosquamous differentiation. 
Hereby we clearly show that an ultra-deep sequencing technology of the entire mt-genome (wmt-seq) is a suitable 
molecular tool for tumour history tracking on pathologically processed FFPE material.
Results and Discussion
In order to track tumourigenesis on FFPE archived material, we developed a novel approach for comprehensive 
mtDNA mutation analysis using a multiplex PCR-based ultra-deep sequencing approach on multifocal NSCLC 
lesions of different histological growth patterns.
For molecular tumour tracking, a PCR-based NGS of the entire mt-genome was established. To generate 
amplicons of a low size (around 60-200 bp), 108 primer sets, spanning the entire mtDNA (Fig. 1A) were designed 
according to the mt-sequence of accession no. NC_012920 or taken from previously published primer sets 
(Supplemental Table S1). Primers were designed to generate overlapping amplicons of 160 bp average length 
to guarantee robust multiplex PCR (Fig. 1B). This design allowed an efficient amplification of small quanti-
ties of highly fragmented DNA (Supplemental Figure S1) as extracted from FFPE material17. Though formalin 
causes high nucleic acid fragmentation and nucleotide modification such as cytosine amination that leads to a 
C > T/ G > A exchange during PCR reactions, it is used world-wide in diagnostic routine-processing of tissues. 
Therefore, our approach is of particular interest for analysis of clinical, formalin-fixed samples. Circulating DNA, 
isolated from plasma and serum samples, is also of low quantity and quality18, 19. Since in the recent past circulat-
ing mtDNA has been highlighted as a prognostic tool in cancer diagnostics20, 21, our technical approach benefits 
from the high efficiency of whole mt-DNA sequencing (wmt-seq) on short DNA fragments.
Previous NGS-based approaches to mtDNA analysis used long-range PCR amplicons, and worked only on 
native material22, 23. Others focused on the analysis of the mt-control region (D-LOOP), which encompasses a 
hotspot region but only covers 7% of the total mt-genome11, 12. The presented robust multiplex PCR, however, 
was used for PCR-based target enrichment, providing an approach to wmt-seq that can be applied to different 
sources of DNA.
Application of ultra-deep wmt-seq on NSCLC lesions. Forty-three nodules from 19 patients with 
NSCLC were studied for tumour heterogeneity by wmt-seq. The FASTQ files generated by wmt-seq of 43 samples 
were applied to bioinformatics analysis. The sequences were mapped against the entire human reference genome 
hg19 to exclude the possibility that nuclear pseudogenes, which have a high homology to parts of the mt-genome, 
were recognised. As a threshold for variant calling, a minimum read depth was set to 30 and the minimum 
variant frequency was set to 5%. Polymorphisms were recognised using the MITOMAP (www.mitomap.org), 
dbSNP-v138 (www.ncbi.nlm.nih.gov/SNP), and HAPMAP_phase_3 (hapmap.ncbi.nlm.nih.gov) databases.
The data analysis output generated an average of 484 × 103 reads per sample. A total of 473 × 103 reads were 
mapped to the mtDNA reference sequence, showing that 96% of the mt-genome was covered by a mean read 
depth of 3.000 reads per 100 bp (Supplemental Table S2). Furthermore, the high sequencing performance was 
demonstrated by nearly 98% run specificity, proven by only 2.5% off-targets reads (Supplemental Table S3).
The good coverage of the mt-genome and the low rate of site-off reads demonstrated the efficiency of the 
designed primer sets and a good run performance for the analysis of the entire mt-genome.
mt-variants identified in NSCLC by wmt-seq. After data filtering, a total of 640 variants were identified 
(Supplemental Figure S2). Most of these mutations were T > C/A > G, G > A/C > T base transitions (Fig. 2A) 
as shown by Kennedy et al.24. In agreement with previous reports9, 10, 25, the highest frequency of variants was 
observed in the D-LOOP regulatory site, which is responsible for the replication and expression of mtDNA 
(178/640, 28%). Furthermore, a high frequency of variants was found in the genes encoding for the respiratory 
chain complexes (Supplemental Figure S2). These mutations could lead to an abnormal metabolism as well as to 
altered apoptosis26, 27. The defined mutations are listed in Supplemental Table S4.
The majority of detected variants were homoplasmic (520/640; 81%) or highly heteroplasmic, as reported 
in previous studies9, 25. Most of the mt-variants might have occurred before tumourigenesis, because germline 
mtDNA polymorphisms generally reach a relatively high percentage of heteroplasmy or even homoplasmy during 
cellular phenotype development28. Some of these mtDNA polymorphisms (Fig. 2B) were previously shown to be 
disease-related and should be considered as possibly pathogenic (c.f. MITOMAP database)29, 30. Furthermore, 
in agreement with the studies of Brandon et al. our data revealed that most of the identified tumour associated 
mtDNA variants (Fig. 2B) are frequent in the general population28. Notably, two of the detected mtDNA popula-
tion polymorphisms, namely mtDNA mutations at nucleotides 10398 and 16189 (Fig. 2B), have been shown to be 
associated with an increased risk of both breast31 and endometrial cancer32. The heteroplasmic T > C exchange at 
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Figure 1. Scheme of primer design and the multiplex PCR-based approach to mt-genome enrichment. Primer 
sets (Table S2) were designed (A) generating 108 amplicons spanning the whole mitochondrial genome (B). 
Four primer pools, each including 27 primer sets, were applied to multiplex PCR according to the GeneRead 
multiplex PCR design of Qiagen, to ensure that overlapping amplicons were generated in separate reaction 
mixes.
Figure 2. Disease-related and base pair transition mt-mutations. Overall frequency of base pair transitions, 
found in NSCLC. T > C:G > A are the most common base pair transitions. Other*: Indels and transversion 
mutations (A). Homoplasmic polymorphisms, previously shown to have a functional impact in different cancer 
types(MITOMAP database) were frequently detected in the NSCLC cohort (n = number of positive samples) (B).
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position 16189 is located in a hypermutable polyC stretch (16184^16193). This mt-microsatellite region as well 
as the one at position 302^315 are therefore appropriate regions to detect mt-DNA instability, which was shown 
previously to be associated with tumour malignancy33, 34.
Functional mtDNA polymorphisms may help tumours to adapt to new environments and actively grow in 
metastatic oxygen-rich conditions28, 35. Therefore, these mtDNA polymorphisms may become fixed and shift from 
initially heteroplasmic to homoplasmic mutations. Somatic tumour-specific mtDNA mutations inhibit oxidative 
phosphorylation, increase ROS production, and promote tumour cell proliferation. These somatic mutations may 
be lost during subsequent tumour oxygenation by replicative segregation, with the cell turning back towards the 
more oxidative mtDNA genotype favoured in the metastatic environment28, 35.
NSCLC tumour-tracking and clonality analysis by wmt-seq. Tracking the tumour cell lineage was 
not possible on samples that carried only homoplasmic mtDNA polymorphisms (i.e. #02, #04, #10 and #11). 
However, sample sets that harboured heteroplasmic somatic mutations, occurring in all of the lesion’s individual 
nodules (trunk mutations), in a subset (branch mutations), or only in one individual nodule (private mutations) 
could be considered for evolution analysis.
Private mutations were only detected in single tumour nodules of particular cases (e.g.66 del-G and G3036A 
mutations in sample #03, T1180C and G12561A mutations in sample #07, G1681A and 12384^12385-ins C muta-
tions in sample #09, and G12125A mutation in sample #14) (Figs 3 and 4, Supplemental Table S4). Most samples 
(i.e. #01, #05, #07, #08, #12, #13, #14, #15, #16, #17, #18 and #19), showed trunk mutations in the different nod-
ules, proving a common cell of origin of the individual nodules (Figs 3 and 4, Supplemental Table S4). Moreover, 
branch mutations were detected in tumour nodules of sample #06, TN3 and TN4, which harboured a T650C 
mutation, whereas TN1, TN2 and TN3 carried a G13480A mutation (Supplemental Table 25, Supplemental 
Figure S3).
Notably, branch mutations in tumour nodules TN2 and TN3 of sample #05 at positions A215G, G2268A 
and G11711A, suggesting that TN2 and TN3 are subclones, derive from TN1. The increasing frequencies of the 
accumulating additional mutations show that they became dominant over time and provide insights about the 
evolutionary mechanisms that drive neoplastic progression (Supplemental Table S4, Supplemental Figure S3).
Thus, heteroplasmic somatic mutations indicate a clonal expansion of mtDNA mutants, which become either 
intra- and intercellularly dominant or submissive (Supplemental Table S4). This is in concordance with our find-
ings that the adenocarcinoma and squamous carcinoma components of the adenosquamous NSCLC sample set 
(ADSQ-NSCLC, group II, Table 1) also share identical genomic hot-spot mutations e.g. in the TP53 and EGFR 
genes36.
Figure 3. Global annotated mt-variants in tumour lesions with different growth patterns (group I). Common 
mt-variants (intersection area), adaptive mt-polymorphisms and somatic mutants occurring in NSCLC 
tumour lesions of cases #01–#06 are illustrated in Venn diagrams (A). Variants are shown according to their 
mt-genomic location and gene regions (B). Adaptive mt-polymorphisms common in all lesions of individual 
sample are labelled in green, whereas somatic mt-mutations with pathogenic impact on some lesions are shown 
in red (c.f. Supplemental Data and Table S4).
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The mtDNA constantly predisposed to mutations that may either expand or be lost during tumour progres-
sion9, 10, 38, 39. As such, mt-mutations are discussed to acquire a selective replicative advantage during cellular 
development and become dominant, evolving a clonal cell population with homoplasmic mutants9, 10, 37. As pre-
viously shown, clonal homoplasmic expansion develops by crypt fission, forming large tumour patches with 
identical mt-mutations38, 39. In agreement, our data demonstrate that tumour nodules of the cases #01, #05, #07, 
#L08 and #12-19 arise within the clonal patch harbouring identical mt-mutations (Supplemental Table S4, Fig. 5).
In conclusion, the established multiplex PCR-based ultra-deep sequencing method may be considered as a 
novel molecular tool for the comprehensive analysis of the entire mt-genome. Though a limited number of private 
and branch variants, which we identified in different nodules, did not allow us to describe the complete evolu-
tionary dynamics of tumor clonal networks2, 3, this technology provides for the first time a highly specific and 
sensitive approach to study the clonal relationship and tumour history on FFPE material of the pathology routine 
processing. This is of particular importance in terms of an appropriate tumour-specific treatment strategy when 
de-novo primary tumours and recurrent cancers have to be differentiated12.
Importantly, due to the tolerance of low DNA quantity and quality, the multiplex PCR-based wmt-seq tech-
nology might also be applicable to cell-free DNA approaches as a novel option to detect mitochondrial DNA 
alterations in various body fluids and to monitor cancer progression and mitochondrial disorders.
Materials and Methods
NSCLC biopsies and DNA extraction. A total of 43 FFPE NSCLC tumour lesions archived from 19 
patients were included in this study (Table 1). Biopsies collected by the Institutes of Pathology at the University 
Hospital of Cologne, Germany, and the University Hospital of Bern, Switzerland, were used with the informed 
consent of the patients and in agreement with the local ethical guidelines as approved by the local ethical com-
missions (‘Biomasota’ biomaterials collection, Az 13-091 and KEK Nr. 200/2014). Multiple lung cancer lesions with 
Figure 4. Global annotated mt-variants in mixed ADSQ samples (group II). Common mt-variants 
(intersection area), adaptive mt-polymorphisms and somatic mutants occurring in NSCLC tumour lesions 
of cases #07–#19 are illustrated in Venn diagrams (A). Variants are shown according to their mt-genomic 
location and gene regions (B). Adaptive mt-polymorphisms common in all lesions of individual sample are 
labelled in green, whereas somatic mt-mutations with pathogenic impact on some lesions are shown in red (c.f. 
Supplemental Data and Table S4).
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different tumour grades or histology (group I) and tumours with intratumoural heterogeneity (group II) were 
characterized by immunohistology (Supplemental Figure S4).
DNA extraction. Lesional areas of NSCLC were marked by senior pathologists (SCS, CT, JM) and nod-
ules with more than 80% were scraped off or -if necessary- laser microdissected as we described previously36. 
Thereafter, DNA was automatically extracted using the Maxwell DNA FFPE isolation kit on a Maxwell platform 
(Promega GmbH, Mannheim, GER) according to the manufacturer’s instructions. PCR accessible DNA was 
determined by qPCR as described previously40, 41. In brief, PCR amplifiable DNA was quantified by real-time PCR 
using the HFE gene as amplifying reference (173 bp). Standard curves in a range of 0.195 to 50 ng were prepared 
from unmutated high quality DNA (Takara Saint-Germain-en-Laye, F). Real-time PCR was then carried out in 
triplicates with 1 µl DNA each, in a 20 µl reaction mix containing 0.4 µM of the HFE forward and reverse primer 
(HFE-173F: TTC TCA GCT CCT GGC TCT CAT C and HFE-173R: TCG AAC CTA AAG ACG TAT TGC CC) 
and the GoTaq® qPCR Master Mix (Promega).
Primer design, multiplex PCR-based library construction and next generation sequencing. To 
generate amplicons of a low size (around 60–200 bp), 108 primer sets spanning the whole mtDNA (Supplemental 
Table S1) were designed according to the mt-sequence of accession no. NC_012920 or taken from previously 
published primer sets (Fig. 1A, Supplemental Table S1). For enrichment of the mt-genome by a multiplex 
PCR, primer sets were pooled in four primer mixes of 2 µM and in each reaction, 10 ng of PCR accessible DNA 
-representing DNA of around 1500 cells was used (Fig. 1B).
mtDNA was then amplified in four separate multiplex PCR reactions per sample using the GeneRead DNAseq 
Panel PCR Kit (QIAGEN Inc., Hilden, GER) in accordance with the manufacturer´s protocol. Libraries were 
pooled and purified using Agencourt® AMPure® XP magnetic beads and a Biomek® FXp workstation (Beckman 
Coulter Inc, Fullerton, CA, USA). Fifty ng enriched targets of each sample were adenylated and ligated to 
NEXTflex™ DNA barcodes-48 (Bioo Scientific, Austin, TX, USA). After Agencourt® AMPure® XP magnetic bead 
purification and size selection, barcoded libraries were amplified by five PCR cycles. Finally, 12 pM of the con-
structed libraries were sequenced using the V2 chemistry of Illumina Inc. (San Diego, CA, USA) and 2 × 300 bp 
sequencing read length on an Illumina MiSeq platform following the manufacturer’s recommendations.
Data filtering and analysis. The FASTQ files generated by the Illumina platform were analysed by 
means of the Biomedical Genomics Workbench 2.5.1 (QIAGEN Inc., Hilden, GER; www.qiagenbioinformat-
ics.com). To determine run performance and off-target reads, the FASTQ sequences were mapped against the 
whole human reference genome hg19. For variant calling and annotation, the mt-genome (Genebank; accession 
no. NC_012920) served as a reference. Using the workflow tool of the Biomedical Genomics Workbench 2.5.1 
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TN2 SQ G3 TN2 SQ G3
Table 1. Histological characteristics of the 43 NSCLC lesions studied by mtDNA analysis. AD: 
adenocarcinoma, SQ: squamous cell carcinoma.
www.nature.com/scientificreports/
7SCIentIfIC REPORTS | 7: 11069  | DOI:10.1038/s41598-017-11345-3
software in batch mode ensured successive and identical analysis of all samples. The minimum read depth was set 
to 30, with the minimum variant frequency set to 5%. Furthermore, variant calling was restricted to loci with a 
balanced forward-backward performance ( > 0.2). Polymorphisms were recognised using the MITOMAP (http://
www.mitomap.org/bin/view.pl/MITO-MAP/HumanMitoSeq), dbSNP-v138 (http://www.ncbi.nlm.nih.gov/
SNP/_id=138) and HAPMAP_phase_3 http://hapmap.ncbi.nlm.nih.gov/hapmap3r3_B36/) databases. Spurious 
calls were subsequently filtered by manual analysis using the integrative genomic viewer of the Biomedical 
Genomics Workbench software. Variants, which occur in different sample sets but with a similar frequency as well 
as variants which were located in repetitive or highly homologous regions of the mt-genome, in high background 
noise regions, or at the end of the amplicons were considered as putative false variants. Potential false positive 
variants were either deleted when they were clearly recognizable as artefacts or were further re-assessed by Sanger 
sequencing. In addition, whenever DNA was still available, the mt-DNA regions carrying a variant in one lesion 
sample but not in another of the same patient sample set, were subsequently re-analysed by conventional Sanger 
sequencing.
Data Availibility. All data generated or analysed during this study are included in this published article and 
its Supplementary Information files. Filtered variant profiles of wmt-seq can be found in supplemental Table 4, 
showing variants of the sample sets in the different excel sheets. Raw data are available as FASTQ sequences at the 
SRA data base (SUB2583044 and SUB2962918).
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